Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Key Inclusion Criteria:

• Willing and able to provide written informed consent.

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed byPCR or an approved alternative assay (eg. Rapid Antigen Test) ≤ 5 days beforerandomization. Serologic tests will not be accepted.

• Initial onset of COVID-19 signs/symptoms ≤ 5 days before randomization.

• Not currently hospitalized or requiring hospitalization.

• Presence of ≥ 1 risk factor (if unvaccinated) or ≥ 2 risk factors (if vaccinated atany point) for progression to severe disease.

Key Exclusion Criteria:

• Anticipated use of COVID-19 therapies during the current COVID-19 illness.

• Received any direct acting antiviral drug against SARS-CoV-2 for the treatment ofCOVID-19 < 28 days or < 5 half-lives, whichever is longer, before randomization.

• Anticipated need for hospitalization < 48 hours after randomization.

• New oxygen requirement < 24 hours before randomization.

• Decompensated cirrhosis (Child-Pugh class B or C) or acute liver injury/failure.

• Undergoing dialysis, or history of moderate to severe renal impairment.

• Pregnant or breastfeeding (nursing).

• Unwilling to use protocol-mandated birth control.

• Received an approved, authorized or investigational COVID-19 vaccine (includingbooster dose) <120 days before randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.